Literature DB >> 24325695

High-grade, non-flow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: an additional analysis from the THUNDER study.

Gunnar Tepe1, Thomas Zeller, Beatrix Schnorr, Claus D Claussen, Ulrich Beschorner, Klaus Brechtel, Bruno Scheller, Ulrich Speck.   

Abstract

PURPOSE: To investigate the impact of using paclitaxel-coated balloons (PCB) on outcome after post-angioplasty dissection in femoropopliteal arteries.
METHODS: The angiograms obtained in the THUNDER study (ClinicalTrials.gov identifier NCT00156624) were analyzed to compare degrees of dissection and angiographic parameters between the control (uncoated balloons, n=43) and treatment (PCBs, n=43) groups before and after the intervention and at 6-month follow-up. Furthermore, target lesion revascularizations (TLR) were documented up to 2 years.
RESULTS: In each group, 24 (56%) patients had a dissection after the intervention. At the 6-month follow-up, patients with dissection of any grade after treatment with PCBs had significantly less late lumen loss (0.4 mm) than patients with dissection after treatment with uncoated balloons (1.9 mm, p=0.001) and a lower degree of stenosis (20% vs. 51%, respectively; p=0.003). Patients with severe dissection (grades C, D, or E) especially seemed to benefit from the PCBs, with late lumen loss of 0.4 mm vs. 2.4 mm for controls (p=0.05). The binary restenosis rate was also markedly lower in the PCB group (20%) than in the uncoated group (55%, p=0.02). In the 2-year follow-up, TLR was performed in 56% of patients in the control group compared to 10% of patients in the PCB group (p=0.002).
CONCLUSION: The results of this subgroup analysis suggest that patients with dissection following treatment with a paclitaxel-coated balloon have a very acceptable outcome and stent implantation is not necessary as long as the dissection does not result in acute flow limitation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24325695     DOI: 10.1583/13-4392R.1

Source DB:  PubMed          Journal:  J Endovasc Ther        ISSN: 1526-6028            Impact factor:   3.487


  10 in total

1.  Drug-coated balloons: how should we incorporate into our practice in treating superficial femoral artery lesions?

Authors:  Thomas Zeller; Aljoscha Rastan; Roland Macharzina; Ulrich Beschorner; Elias Noory
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-05

2.  Clinical outcomes and predictors of restenosis in patients with femoropopliteal artery disease treated using polymer-coated paclitaxel-eluting stents or drug-coated balloons.

Authors:  Naoki Yoshioka; Takahiro Tokuda; Akio Koyama; Takehiro Yamada; Ryusuke Nishikawa; Kiyotaka Shimamura; Kensuke Takagi; Yasuhiro Morita; Akihito Tanaka; Hideki Ishii; Itsuro Morishima; Toyoaki Murohara
Journal:  Heart Vessels       Date:  2021-09-22       Impact factor: 2.037

Review 3.  Novel Approaches to the Management of Advanced Peripheral Artery Disease: Perspectives on Drug-Coated Balloons, Drug-Eluting Stents, and Bioresorbable Scaffolds.

Authors:  Thomas Zeller; Aljoscha Rastan; Roland Macharzina; Ulrich Beschorner; Elias Noory
Journal:  Curr Cardiol Rep       Date:  2015-09       Impact factor: 2.931

4.  Association between post-balloon angioplasty dissection and primary patency in complex femoropopliteal artery disease: 2-year clinical outcomes of the AcoArt I trial.

Authors:  Hao Ren; Jie Liu; Jiwei Zhang; Baixi Zhuang; Weiguo Fu; Danming Wu; Feng Wang; Yu Zhao; Pingfan Guo; Wei Bi; Shenming Wang; Wei Guo
Journal:  J Int Med Res       Date:  2021-04       Impact factor: 1.671

5.  Treatment of infrapopliteal post-PTA dissection with tack implants: 12-month results from the TOBA-BTK study.

Authors:  Marianne Brodmann; Christian Wissgott; Andrew Holden; Robert Staffa; Thomas Zeller; Thodur Vasudevan; Peter Schneider
Journal:  Catheter Cardiovasc Interv       Date:  2018-03-24       Impact factor: 2.692

6.  Five-Year Outcomes of Post-Drug-Coated Balloon Angioplasty Dissection in Complex Femoropopliteal Artery Disease.

Authors:  Hao Ren; Jie Liu; Jiwei Zhang; Baixi Zhuang; Weiguo Fu; Danming Wu; Feng Wang; Yu Zhao; Pingfan Guo; Wei Bi; Shenming Wang; Wei Guo
Journal:  Int J Gen Med       Date:  2021-08-05

7.  How Much Debulking with Atherectomy is Enough When Treating Infrainguinal Arterial Interventions? The Balance Between Residual Stenosis and Adventitial Injury.

Authors:  Nicolas W Shammas
Journal:  Vasc Health Risk Manag       Date:  2022-04-05

Review 8.  Critical appraisal of paclitaxel balloon angioplasty for femoral-popliteal arterial disease.

Authors:  Monika Herten; Giovanni B Torsello; Eva Schönefeld; Stefan Stahlhoff
Journal:  Vasc Health Risk Manag       Date:  2016-08-29

Review 9.  Current developments in endovascular therapy of peripheral vascular disease.

Authors:  Damianos G Kokkinidis; Ehrin J Armstrong
Journal:  J Thorac Dis       Date:  2020-04       Impact factor: 3.005

10.  Outcomes of Dissection Angles as Predictor of Restenosis after Drug-Coated Balloon Treatment.

Authors:  Amane Kozuki; Mitsuyoshi Takahara; Masahiro Shimizu; Yoichi Kijima; Ryoji Nagoshi; Ryudo Fujiwara; Hiroyuki Shibata; Atsushi Suzuki; Fumitaka Soga; Tomohiro Miyata; Yuki Sakamoto; Hidenobu Seo; Hiroyuki Asada; Kouhei Isawa; Kotaro Higuchi; Junya Shite
Journal:  J Atheroscler Thromb       Date:  2020-10-23       Impact factor: 4.928

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.